Noxxon Pharma makes addition to supervisory board
This article was originally published in Scrip
Executive Summary
Berlin, Germany and Boston, USA-based Noxxon Pharma has named Don deBethizy to the company's supervisory board. In his last position as president and chief executive officer of Santaris Pharma, Mr deBethizy initiated and managed the successful acquisition of the company by Roche. Previously, he was executive chair of Danish bio-venture firm, Contera Pharma. Noxxon is developing a new class of proprietary therapeutics called Spiegelmers, which are chemically synthesized L-stereoisomer oligonucleotide aptamers, a non-immunogenic alternative to antibodies.
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.